rs17249754 — ATP2B1

Intronic variant in the ATP2B1 calcium pump gene; the common G allele reduces PMCA1 expression in vascular tissue, impairing calcium efflux and raising blood pressure — one of the most replicated blood pressure GWAS loci across Asian and European populations

See your personal result for ATP2B1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ATP2B1 rs17249754 — A Second Calcium Pump Variant Tuning Blood Pressure

Running just 80 kilobases downstream of the widely-studied rs2681472 variant at the same gene, rs17249754 is an independent intronic variant in ATP2B111 ATP2B1
encodes Plasma Membrane Ca²⁺-ATPase 1 (PMCA1), the primary pump ejecting calcium from inside cells to the extracellular space — essential for maintaining low intracellular calcium in vascular smooth muscle. Like its neighboring variant, rs17249754 has reached genome-wide significance in multiple large international consortia, but its risk story has an unusual twist: the common G allele (~83% in Europeans, ~65% in East Asians) is the blood pressure-raising allele, while the rarer A allele is protective. Most people carry at least one G allele without knowing it.

The Mechanism

rs17249754 sits within an intron of ATP2B1 on chromosome 12q21.33, position 89,666,809 (GRCh38)22 chromosome 12q21.33, position 89,666,809 (GRCh38). The intronic location means it does not alter the protein sequence of PMCA1 directly; instead, it acts as a regulatory variant affecting gene expression levels in vascular tissue. The G allele is associated with reduced ATP2B1 expression in arterial and aortic endothelial cells — fewer functional PMCA1 pumps per cell.

PMCA1 is the dominant calcium extrusion mechanism in vascular smooth muscle cells. When pump density falls, intracellular calcium rises, driving sustained smooth muscle contraction and vasoconstriction. Separately, PMCA1 physically associates with eNOS33 eNOS
endothelial nitric oxide synthase, which produces the vasodilator nitric oxide: impaired PMCA1 activity reduces eNOS output, removing a key vasodilatory signal. Both effects — higher calcium and lower nitric oxide — converge on elevated vascular resistance and raised blood pressure.

Mouse models directly validate this pathway: heterozygous PMCA1-null animals develop elevated blood pressure, and vascular smooth muscle-specific knockout mice show increased intracellular calcium with hypertension. Strikingly, aging heterozygous PMCA1-null mice exhibit arterial wall thickening and lumen narrowing before blood pressure rises44 aging heterozygous PMCA1-null mice exhibit arterial wall thickening and lumen narrowing before blood pressure rises, suggesting subclinical vascular remodelling may precede measurable hypertension by years.

The Evidence

The ICBP consortium analysis55 ICBP consortium analysis
International Consortium for Blood Pressure Genome-Wide Association Studies in approximately 200,000 European-ancestry participants placed rs17249754 among 29 genome-wide significant blood pressure loci: each G allele raises systolic BP by 0.928 mmHg (p=1.8×10⁻¹⁸) and diastolic BP by 0.522 mmHg (p=1.2×10⁻¹⁴). These effect sizes are per-allele, meaning GG homozygotes carry approximately 1.86 mmHg higher systolic and 1.04 mmHg higher diastolic BP than the rare AA genotype.

The original Korean discovery66 original Korean discovery in 16,703 Korean participants (KARE and Health2 cohorts) found rs17249754 was the strongest ATP2B1 signal for hypertension (p=4.25×10⁻⁹) — stronger than the neighboring rs2681472, which predominates in European analyses. A 2021 meta-analysis of 65,362 individuals across 9 studies77 2021 meta-analysis of 65,362 individuals across 9 studies confirmed the association globally: hypertension OR=1.19 (95%CI 1.10–1.28) per G allele. Cross-ethnic replication in 55,383 East Asian participants (stage 1+2)88 in 55,383 East Asian participants (stage 1+2) confirmed the locus for mean arterial pressure (p=7.5×10⁻¹⁵) and pulse pressure (p=1.2×10⁻⁵). Replication extends to African (Burkina Faso), Chinese children, and South Asian populations.

A critical dietary interaction has been documented. In a Korean cohort of 14,354 participants99 Korean cohort of 14,354 participants, G allele (major allele) carriers showed substantially higher systolic BP risk when calcium intake was low and the dietary sodium-to-potassium ratio was high. Conversely, A allele carriers (the protective minority) gained the greatest benefit from high potassium intake and a low sodium-to-potassium ratio. This gene-diet interaction is directly actionable: PMCA1 insufficiency from the G allele is exacerbated when dietary calcium is unavailable to compensate for impaired efflux.

Practical Actions

For GG carriers, three strategies target the underlying mechanism most directly. Maintaining dietary calcium at 1,000–1,200 mg/day is the most genotype-specific intervention: low calcium amplifies the blood pressure risk from reduced PMCA1 activity at a cellular level. Reducing the dietary sodium-to-potassium ratio — through sodium reduction and potassium-rich foods — addresses the salt-sensitivity component documented in this variant's cohort studies. Regular home blood pressure monitoring enables early detection of the gradual pressure elevation this variant drives. For AG heterozygotes, the same dietary targets apply with attenuated urgency — the additive effect model means they carry approximately half the genotype-attributable BP elevation.

Interactions

rs17249754 and rs2681472 are both intronic ATP2B1 variants in partial linkage disequilibrium. rs2681472 is the stronger signal in European-ancestry GWAS; rs17249754 is stronger in East Asian cohorts. Carriers of risk alleles at both variants may have compounded calcium-mediated BP elevation, though formal compound action studies documenting the interaction effect are not yet published.

Within the blood pressure regulatory network, ATP2B1 interacts functionally with AGT (rs699, angiotensinogen M235T) and NOS3 (rs1799983, eNOS Glu298Asp). Angiotensin II elevates intracellular calcium in vascular smooth muscle — a signal that depends on PMCA1 for clearance. Reduced PMCA1 in G allele carriers means angiotensin II-driven calcium signals persist longer. Similarly, impaired PMCA1 reduces the calcium/calmodulin signal available to activate eNOS, compounding the effect of any eNOS Glu298Asp-associated nitric oxide deficit.

Nutrient Interactions

calcium increased_need
sodium altered_metabolism
potassium increased_need

Genotype Interpretations

What each possible genotype means for this variant.

AA Protective Genotype Normal

Lower blood pressure risk — carries the protective A allele at both copies

You carry two copies of the A allele at rs17249754, the rarer protective genotype found in approximately 3% of people globally. This genotype is associated with higher ATP2B1 expression in vascular tissue and more efficient PMCA1 calcium pump activity, keeping intracellular calcium lower and supporting nitric oxide signaling. Your blood pressure contribution from this locus is the lowest possible. This does not eliminate cardiovascular risk from other sources, but the ATP2B1 rs17249754 locus is not a driver of elevated blood pressure for you.

AG One Risk Allele Intermediate

Moderately elevated blood pressure risk — one G allele at this ATP2B1 variant

The additive model confirmed across multiple cohorts means AG carriers average approximately 0.93 mmHg higher systolic and 0.52 mmHg higher diastolic BP compared to AA carriers. Hypertension risk in AG carriers is intermediate (roughly OR 1.10 compared to AA). The dietary calcium and sodium interactions documented for this locus in Korean cohort studies apply to AG carriers with attenuated effect sizes.

The eQTL effect of the G allele on ATP2B1 expression is present with one copy, reducing PMCA1 pump density in arterial tissue and modestly impairing calcium efflux and nitric oxide production. The risk is clinically meaningful when combined with dietary factors that amplify it.

GG Highest Risk Genotype High Risk

Highest blood pressure risk — two copies of the G allele reduce PMCA1 calcium efflux

The ICBP meta-analysis of approximately 200,000 European-ancestry participants placed rs17249754 among 29 genome-wide significant blood pressure loci (p=1.8×10⁻¹⁸ for SBP, p=1.2×10⁻¹⁴ for DBP). A 2021 meta-analysis of 65,362 participants across 9 studies confirmed hypertension OR=1.19 per G allele (95%CI 1.10–1.28). GG homozygotes carry approximately 37–40% higher odds of developing hypertension compared to AA carriers.

The dietary calcium interaction is particularly relevant for GG carriers: a Korean cohort study (n=14,354) documented substantially higher systolic BP risk in G allele (major allele) carriers at low calcium intake and high sodium-to-potassium ratio. Adequate calcium partially compensates for reduced PMCA1 efflux capacity by maintaining calcium gradients at the vascular cell level. High potassium provides additional benefit by activating the sodium-potassium pump, supporting the overall electrochemical environment that PMCA1 requires to function efficiently.

Vascular remodelling may precede measurable hypertension: mouse models of PMCA1 haploinsufficiency show arterial wall thickening and lumen narrowing years before blood pressure rises. This implies early monitoring is more valuable than waiting for frank hypertension to appear.